3Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: From bench to bedside

Cellular and Molecular Life Sciences

Volumn 68, Issue 14, 2011, Pages 2419-2432

  Castella, Barbara ^a   Vitale, Candida ^a   Coscia, Marta ^a   Massaia, Massimo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b Divisione di Ematologia   (Italy)

Author keywords

Immunotherapy; Lymphoma; Mevalonate pathway; MM; V 9v 2 T cells; Zoledronic acid

Indexed keywords

2 METHYL 3 BUTENYL 1 PYROPHOSPHATE; ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BROMOHYDRIN PYROPHOSPHATE; CLODRONIC ACID; IBANDRONIC ACID; IMATINIB; INTERLEUKIN 2; MEVALONIC ACID; MONOETHYLPYROPHOSPHATE; NATURAL KILLER CELL RECEPTOR NKG2D; PAMIDRONIC ACID; PHOSPHOANTIGEN DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; GAMMA DELTA T LYMPHOCYTE; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; NONHUMAN; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE ACTIVATION; BIOLOGICAL MODEL; BLOOD DISEASE; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

CYTOKINES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 79960960603     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0704-8     Document Type: Review

References (92)

1. Landgren O, Kyle RA (2007) Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases. Br J Haematol 139:717-723 (Pubitemid 350115730)
2. Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC (2010) Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 24:512-520
3. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, Krasovsky J (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197: 1667-1676 (Pubitemid 36745342)
4. Girlanda S, Fortis C, Belloni D, Ferrero E, Ticozzi P, Sciorati C, Tresoldi M, Vicari A, Spies T, Groh V, Caligaris-Cappio F, Ferrarini M (2005) MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated gd lymphocytes. Cancer Res 65:7502-7508 (Pubitemid 41161286)
5. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37-50
6. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, Foglietta M, Palumbo A, Coscia M, Castella B, Bruno B, Bertieri R, Boano L, Boccadoro M, Massaia M (2005) Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19:664-670 (Pubitemid 40521173)
7. Burjanadzé M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, Romagne F, Morel Y, Rossi JF, Klein B, Lu ZY (2007) In vitro expansion of gamma delta T cells with antimyeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 139:206-216
8. Thedrez A, Sabourin C, Gertner J, Devilder MC, Allain-Maillet S, Fournié JJ, Scotet E, Bonneville M (2007) Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev 215:123-135
9. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI (2010) Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 116:1726-1733
10. Fisch P, Malkovsky M, Braakman E, Sturm E, Bolhuis RL, Prieve A, Sosman JA, Lam VA, Sondel PM (1990) γδ T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complexrestricted cytolysis. J Exp Med 171:1567-1579 (Pubitemid 20167551)
11. Fisch P, Malkovsky M, Kovats S, Sturm E, Braakman E, Klein B, Voss SD, Morrissey LW, De Mars R, Welch WJ (1990) Recognition by human Vγ9/Vδ2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science 250:1269-1273 (Pubitemid 120031842)
12. Fisch P, Meuer E, Pende D, Rothenfuber S, Viale O, Kock S, Ferrone S, Fradelizi D, Klein G, Moretta L, Rammensee HG, Boon T, Coulie P, van der Bruggen P (1997) Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role of human Vγ9/Vδ2 T cells in tumor immunità. Eur J Immunol 27:3368-3379 (Pubitemid 28018034)
13. Sturm E, Braakman E, Fisch P, Vreugdenhil RJ, Sondel P, Bolhuis RL (1990) Human Vγ9-Vδ2 T cell receptor-γδ lymphocytes show specificity to Daudi Burkitt's lymphoma cells. J Immunol 145:3202-3208
14. Street SE, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM, Diefenbach A, Yagita H, Godfrey DI, Smyth MJ (2004) Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 199:879-884 (Pubitemid 38375207)
15. Selin LK, Stewart S, Shen C, Mao HQ, Wilkins JA (1992) Reactivity of γδT cells induced by the tumour cell line RPMI 8226: functional heterogeneity of clonal populations and role of GroEL heat shock proteins. Scand J Immunol 36:107-117
16. Zheng B, Lam C, Im S, Huang G, Luk W, Lau S, Yau KS, Wong CK, Yao K, Ng MH (2001) Distinct tumour specificity and IL-7 requirements of CD56- and CD56+ subsets of human gd T Cells. Scand J Immunol 53:40-48 (Pubitemid 32113355)
17. Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N (2001) Targeting of tumor cells for human γδ T cells by nonpeptide antigens. J Immunol 167:5092-5098 (Pubitemid 33009743)
18. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G (2003) Human T cell receptor γδ cells recognized endogenous mevalonate metabolites in tumor cells. J Exp Med 19:163-168 (Pubitemid 36152311)
19. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR (1995) Natural and synthetic non-peptide antigens recognized by human gd T cells. Nature 375:155-158
20. Jomaa H, Feurle J, Luhs K, Kunzmann V, Tony HP, Herderich M, Wilhelm M (1999) Vg9/Vd2 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis. FEMS Immunol Med Microbiol 25:371-378 (Pubitemid 29397507)
21. Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, Romagné F, Brailly H, Bonneville M, Fournié JJ (2001) Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem 276:18337-18344
22. Tanaka Y, Kobayashi H, Terasaki T, Toma H, Aruga A, Uchiyama T, Mizutani K, Mikami B, Morita CT, Minato N (2007) Synthesis of pyrophosphate-containing compounds that stimulate Vgamma2Vdelta2 T cells: application to cancer immunotherapy. Med Chem 3:85-99 (Pubitemid 46062346)
23. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, Guggino G, Meraviglia S, Caccamo N, Messina A, Salerno A, Di Raimondo F, Vigneri P, Stassi G, Fourniè JJ, Dieli F (2010) Vgamma9Vdelta2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinibresistant chronic myelogenous leukemia cells. J Immunol 184:3260-3268
24. Kato Y, Tanaka Y, Tanaka H, Yamashita S, Minato N (2003) Requirement of species-specific interactions for the activation of human gamma delta T cells by pamidronate. J Immunol 170:3608-3613 (Pubitemid 36359229)
25. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430
26. Harwood HJ Jr, Alvarez IM, Noyes WD, Stacpoole PW (1991) In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. J Lipid Res 32:1237-1252
27. Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW (2007) Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 110:2674-2684 (Pubitemid 47523192)
28. Fortuny J, de Sanjose S, Becker N, Maynadie' M, Cocco PL, Staines A, Foretova L, Vornanen M, Brennan P, Nieters A, Alvaro T, Moffetta P (2006) Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev 15:921-925 (Pubitemid 43823519)
29. Li J, Herold MJ, Kimmel B, Müller I, Rincon-Orozco B, Kunzmann V, Herrmann T (2009) Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells. J Immunol 182:8118-8124
30. Thompson K, Rogers MJ (2004) Statins prevent bisphosphonateinduced gd-T-cell proliferation and activation in vitro. J Bone Miner Res 19:278-288 (Pubitemid 38116742)
31. Mönkkönen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, Mönkkönen J (2006) A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogencontaining bisphosphonates. Br J Pharmacol 147:437-445
32. Scotet E, Martinez LO, Grant E, Barbaras R, Jenö P, Guiraud M, Monsarrat B, Saulquin X, Maillet S, Estève JP, Lopez F, Perret B, Collet X, Bonneville M, Champagne E (2005) Tumor recognition following Vg9Vd2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22:71-80 (Pubitemid 40143452)
33. Mookerjee-Basu J, Vantourout P, Martinez LO, Perret B, Collet X, Périgaud C, Peyrottes S, Champagne E (2010) F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells. J Immunol 184:6920-6928
34. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384-392 (Pubitemid 30463353)
35. Roelofs AJ, Jauhiainen M, Mönkkönen H, Rogers MJ, Mönkkönen J, Thompson K (2009) Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144:245-250
36. Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B, Pantaleoni F, Foglietta M, Boccadoro M, Massaia M (2007) Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 110:921-927 (Pubitemid 47267430)
37. Gomes AQ, Correia DV, Grosso AR, Lança T, Ferreira C, Lacerda JF, Barata JT, Silva MG, Silva-Santos B (2010) Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells. Haematologica 95:1397-1404
38. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T (1996) Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 93:12445-12450 (Pubitemid 26367163)
39. Stephens HA (2001) MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol 22:378-385
40. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T (2001) Costimulation of CD8ah T cells by NKG2D via engagement by MIC induced on virus infected cells. Nat Immunol 2:255-260 (Pubitemid 33706003)
41. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T (1999) Broad tumor-associated expression and recognition by tumor-derived gd T cells of MICA and MICB. Proc Natl Acad Sci USA 96:6879-6884 (Pubitemid 29274978)
42. Salih HR, Antropius H, Gieseke F (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102:1389-1396 (Pubitemid 36988048)
43. Carbone E, Neri P, Mesuraca M (2005) HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105:251-258
44. Kunzmann V, Wilhelm M (2005) Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma 46:671-680
45. Lança T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C, Ramalho JS, Barata JT, Moita LF, Gomes AQ, Silva-Santos B (2010) The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gamma}{delta T-cell cytotoxicity. Blood 115:2407-2411
46. Uchida R, Ashihara E, Sato K, Kimura S, Kuroda J, Takeuchi M, Kawata E, Taniguchi K, Okamoto M, Shimura K, Kiyono Y, Shimazaki C, Taniwaki M, Maekawa T (2007) Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun 354:613-618 (Pubitemid 46161370)
47. Kunzmann V, Bauer E, Wilhelm M (1999) Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340:737-738
48. Saito A, Narita M, Yokoyama A, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Fuse I, Aizawa Y, Shinada S, Takahashi M (2007) Enhancement of anti-tumor cytotoxicity of expanded gammadelta T cells by stimulation with monocyte-derived dendritic cells. J Clin Exp Hematop 47:61-72
49. Saitoh A, Narita M, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Aizawa Y, Shinada S, Takahashi M (2008) Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma. Med Oncol 25:137-147
50. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102:200-206 (Pubitemid 36759655)
51. Kiladjian JJ, Visentin G, Viey E, Chevret S, Eclache V, Stirnemann J, Bourhis JH, Chouaib S, Fenaux P, Caignard A (2008) Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica 93:381-389 (Pubitemid 351398639)
52. Bonneville M, O'Brien RL, Born WK (2010) Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 10:467-478
53. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M (2010) Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14:2803-2815
54. Malkovska V, Cigel FK, Armstrong N, Storer BE, Hong R (1992) Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency. Cancer Res 52:5610-5616
55. Chen J, Niu H, He W, Ba D (2001) Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes. Int Arch Allergy Immunol 125:256-263 (Pubitemid 32722298)
56. Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, Cendron D, Gross E, Lepage JF, Quillet-Mary A, Ysebaert L, Laurent G, Sicard H, Fournié JJ (2009) Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 113:4875-4884
57. Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s-6230s
58. Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, Mangialardi G, Bertieri R, Coluccia AM, Ribatti D, Dammacco F, Vacca A (2007) Zoledronic acid affects overangiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 6:3256-3262
59. Moschetta M, Di Pietro G, Ria R, Gnoni A, Mangialardi G, Guarini A, Ditonno P, Musto P, D'Auria F, Ricciardi MR, Dammacco F, Ribatti D, Vacca A (2010) Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 46:420-429
60. Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623-633 (Pubitemid 39578752)
61. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP (2007) Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 67:11438-11446 (Pubitemid 350248572)
62. Morgan G, Davies FE, Gregory WM, Bell SE, Szubert AJ, Drayson MT, Ashcroft J, Owen RG, Cook G, Ross FM, Jackson GH, Russell NH, Child JA (2010) Optimising bone disease in myeloma; Zoledronic Acid plus Thalidomide combinations improves survival and bone endpoints: results of the MRC Myeloma IX Trial. In: ASH Annual Meeting, abstract 311
63. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A (2003) Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102:2310-2311 (Pubitemid 37122416)
64. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, Salerno A, Eberl M, Hayday AC (2007) Targeting human gamma}delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67:7450-7457 (Pubitemid 47206575)
65. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F, Hayday AC (2010) In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 161:290-297
66. Bennouna J, Medioni J, Rolland F, Misset JL, Campone M, Sicard H, Tiollier J, Romagne F, Douillard JY, Calvo F (2005) Phase I clinical trial of BromoHydrinPyroPhosphate, BrHPP (Phosphostim), a Vg9Vd2 T lymphocytes agonist in combination with low dose Interleukin-2 in patients with solid tumors. In: ASCO annual meeting
67. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H (2007) Safety profile and antitumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56:469-476 (Pubitemid 46204533)
68. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Négrier S (2008) Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57:1599-1609
69. Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, Goto S, Yokokawa K, Suzuki K (2009) Clinical and immunological evaluation of zoledronate- activated Vgamma9 gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 37:956-968
70. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ (2008) Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68:190-197 (Pubitemid 351380120)
71. Gross E, L'Faqihi-Olive FE, Ysebaert L, Brassac M, Struski S, Kheirallah S, Fournié JJ, Laurent G, Quillet-Mary A (2010) B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells. Leukemia 24:1885-1892
72. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Goodell MA, Heslop HE, Brenner MK (2010) Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia 24:563-572
73. Scheper RJ, Dalton WS, Grogan TM, Schlosser A, Bellamy WT, Taylor CW, Scuderi P, Spier C (1991) Altered expression of P-glycoprotein and cellular adhesion molecules on human multidrug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity. Int J Cancer 48:562-567
74. Shtil AA, Turner JG, Durfee J, Dalton WS, Yu H (1999) Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 93:1831-1837 (Pubitemid 29128483)
75. Dieli F, Troye-Blomberg M, Ivanyi J, Fournié JJ, Krensky AM, Bonneville M, Peyrat MA, Caccamo N, Sireci G, Salerno A (2001) Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T lymphocytes. J Infect Dis 184:1082-1085 (Pubitemid 32955129)
76. Qin G, Mao H, Zheng J, Sia SF, Liu Y, Chan PL, Lam KT, Peiris JS, Lau YL, Tu W (2009) Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J Infect Dis 200:858-865
77. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, Orlando V, La Mendola C, Gulotta G, Salerno A, Dieli F, Stassi G (2009) Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 182:7287-7296
78. Galimberti S, Benedetti E, Morabito F, Petrini I, Battolla B, Papineschi F, Fazzi R, Ciabatti E, Martino M, Cuzzola M, Console G, Iacopino P, Petrini M (2006) Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Leuk Res 30:529-535 (Pubitemid 43374580)
79. Kunzmann V, Kimmel B, Herrmann T, Einsele H, Wilhelm M (2009) Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells. Immunology 126:256-267
80. Gong G, Shao L, Wang Y, Chen CY, Huang D, Yao S, Zhan X, Sicard H, Wang R, Chen ZW (2009) Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+ Foxp3+ T regulatory cells in mycobacterial infection. Blood 113:837-845
81. Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, Turlin B, Mönkkönen H, Mönkkönen J, Boudjema K, Catros V, Bouet-Toussaint F (2010) Aminobisphosphonatepretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother 59:1611-1619
82. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foà R, Santoni A (2009) ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113:3503-3511
83. Wang X, Lundgren AD, Singh P, Goodlett DR, Plymate SR, Wu JD (2009) An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit shedding. Biochem Biophys Res Commun 387:476-481
84. Benson D, Bakan CE, Zhang S, Alghothani L, Liang J, Hofmeister C, Srivastava S, Smith MK, Greenfield CN, Andre P, Squiban P, Romagne F, Caligiuri MA, Farag S (2009) IPH2101, a novel anti-inhibitory KIR monoclonal antibody, and Lenalidomide combine to enhance the natural killer (NK) cell versus multiple myeloma (MM) effect. In: ASH annual meeting, abstract 3870
85. Gaidarova, Corral LG, Gleizer E, Young D, Brady H, Bennett B, Lopez-Girona A (2009) Lenalidomide enhances anti-tumor effect of γδ T cells against mantle cell lymphoma. In: ASH annual meeting, abstract 2616
86. Cui Q, Abe M, Miki H, Nakamura S, Watanabe K, Ikegame A, Hiasa M, Nakano A, Harada T, Fujii S, Kagawa K, Takeuchi K, Ozaki S, Matsumoto T (2010) Lenalidomide in combination with Zoledronic Acid restores the activation and anti-myeloma effects of γδT cells attenuated by the bone marrow microenvironment. In: ASH annual meeting, abstract 3124
87. Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD Jr, Barlogie B, van Rhee F (2008) Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 111:1309-1317 (Pubitemid 351213417)
88. Rey J, Veuillen C, Vey N, Bouabdallah R, Olive D (2009) Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors. Trends Mol Med 15:275-284
89. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, Fai-So H, Moriyasu F, Nieda M, Nicol AJ (2008) Vgamma9Vdelta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - rituximab and trastuzumab. Int J Cancer 122:2526-2534 (Pubitemid 351590486)
90. Rossi JF, Solal-Celigny P, Soubeyran P, Delvail V, Ghesquieres H, Thieblemont C, Jourdan E, Kunzmann V, Feugier P, Casasnovas RO, Le Gouill S, van den Neste E, Lafaye De Micheaux S, Marzetto M, Beautier L, Squiban P, Sicard H, Laurent G (2010) A phase I/II study of IPH1101, gamma delta T cell agonist, in combination with Rituximab re-treatment, in patients with low grade follicular lymphoma. In: EHA annual meeting, abstract 1131
91. Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, Breitmeyer JB, Weiner GJ (2006) Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108: 2648-2654
92. de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, Béliard R, Vieillard V, Cazin B, Bourel D, Prost JF, Teillaud JL, Merle-Béral H (2008) Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 140:635-643 (Pubitemid 351300917)